BioNTech SE (BNTX) Non-Current Assets (2018 - 2026)
BioNTech SE (BNTX) posted Non-Current Assets of $6.8 billion for Q4 2025, up 5.56% sequentially from $6.4 billion in Q3 2025, and up 70.79% YoY from $4.0 billion in Q4 2024.
Analysis
BioNTech SE (BNTX) Non-Current Assets (2018 - 2026) Analysis & Trends
BioNTech SE has reported Non-Current Assets for 8 years, with the latest figure at $6.8 billion in Q4 2025.
- Quarterly Non-Current Assets rose 70.79% year-over-year to $6.8 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $25.5 billion (up 51.46% YoY) and the FY2025 annual result came in at $6.6 billion, up 65.76% from the prior year.
- Non-Current Assets climbed to $6.8 billion in Q4 2025 per BNTX's latest filing, from $6.4 billion in the prior quarter.
- Over five years, Non-Current Assets peaked at $6.8 billion in Q4 2025 and troughed at $803.3 million in Q3 2021.
- A 5-year average of $3.2 billion and a median of $3.5 billion in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets surged 224.44% in 2023, then climbed 6.37% in 2024.
- Over 5 years, Non-Current Assets stood at $867.7 million in 2021, then jumped by 59.57% to $1.4 billion in 2022, then surged by 170.35% to $3.7 billion in 2023, then climbed by 6.37% to $4.0 billion in 2024, then soared by 70.79% to $6.8 billion in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $6.8 billion, $6.4 billion, and $6.5 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.15 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 294.93 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.96 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 18.06 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 468.65 Mn |
| 10 | BioNTech SE | 25.06 Bn | 11.41 Bn | 10.00 Mn | 5.86 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.86 Bn |
| Mar 31, 2026 | 6.49 Bn |
| Dec 31, 2025 | 6.80 Bn |
| Sep 30, 2025 | 6.44 Bn |
| Jun 30, 2025 | 6.46 Bn |
| Mar 31, 2025 | 5.85 Bn |
| Dec 31, 2024 | 3.98 Bn |
| Sep 30, 2024 | 4.30 Bn |
| Jun 30, 2024 | 4.26 Bn |
| Mar 31, 2024 | 4.33 Bn |
| Dec 31, 2023 | 3.74 Bn |
| Sep 30, 2023 | 3.76 Bn |
| Jun 30, 2023 | 3.28 Bn |
| Mar 31, 2023 | 2.14 Bn |
| Dec 31, 2022 | 1.38 Bn |
| Sep 30, 2022 | 1.40 Bn |
| Jun 30, 2022 | 1.01 Bn |
| Mar 31, 2022 | 935.47 Mn |
| Dec 31, 2021 | 867.70 Mn |
| Sep 30, 2021 | 803.33 Mn |